Protein arginine methyltransferase 7 (PRMT7) plays a crucial role in tumor occurrence and development; however, its expression pattern, biological function, and specific mechanism in gastric cancer (GC) remain poorly defined. The present study aimed to investigate the role of PRMT7 during GC carcinogenesis and its underlying mechanism. We found that PRMT7 is expressed at low levels in GC tissues, and this low expression is associated with tumor size, differentiation degree, lymph node metastasis, and TNM stage. Functionally, PRMT7 inhibits GC cell proliferation and migration. Mechanistically, PRMT7 induces PTEN expression and suppresses the downstream PI3K/AKT signaling cascade. Finally, we confirmed that PRMT7 interacts with PTEN protein and promotes PTEN arginine methylation. Taken together, our findings suggest that PRMT7 can inhibit PI3K/AKT signaling pathway activation by regulating PTEN, thereby inhibiting GC cell proliferation and migration. PRMT7 may be a promising therapeutic target for the prevention of GC.
10 January 2025 in International Immunopharmacology
CCHC zinc finger protein 10 (ZCCHC10) has been implicated in the progression of multiple malignancies, but its prognostic value and role in immune infiltration in breast cancer remain unclear. In this study, we systematically analyzed ZCCHC10 expression using public databases and validated the findings by immunohistochemistry. Associations with clinicopathological features and patient prognosis were assessed, and a prognostic nomogram was constructed. Co-expression networks and gene set enrichment analysis were used to explore functional pathways, while immune infiltration was evaluated and potential therapeutic agents were predicted. Functional assays, including proliferation and colony formation experiments, were performed to examine the biological role of ZCCHC10 in vitro. Our results demonstrated that ZCCHC10 was significantly upregulated in breast cancer and associated with poor prognosis and adverse clinicopathological characteristics. Enrichment analysis indicated involvement in immune-related pathways, and its expression correlated with immune cell infiltration and immunomodulators. Drug sensitivity prediction suggested Ipatasertib as a candidate targeted therapy requiring experimental verification. Knockdown of ZCCHC10 markedly inhibited breast cancer cell proliferation. Collectively, these findings suggest that ZCCHC10 serves as a prognostic biomarker and a key regulator of immune infiltration in breast cancer.